Protocol Ledger

NCT04367311 · Phase II · ACTIVE NOT RECRUITING

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (N

Interventional Phase II clinical trial protocol NCT04367311 sponsored by Nasser Hanna in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-22 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04367311
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04367311
Protocol FieldVerified Registry Value
NCT IdentifierNCT04367311
Consolidated Lead SponsorNasser Hanna
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2020-05-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI